Perioperative Complications in Patients with Systemic Sclerosis: A Comparative Cohort Analysis A Comparative Cohort Analysis
Main Article Content
Abstract
Background: Systemic sclerosis (SSc) is a rare autoimmune disorder with pathological manifestations affecting multiple organ systems. Few studies have examined perioperative outcomes in patients with this disorder. The primary aim of this retrospective single-center comparative cohort analysis was to estimate the incidence of select perioperative complications in a population of SSc patients. In an exploratory analysis, we analyzed the relationship between SSc and susceptibility to select perioperative complications when treated at a large quaternary-care institution.
Methods: We conducted a single-center retrospective, comparative cohort study to compare perioperative outcomes in a SSc (n=258) and a frequency matched control cohort (n=632). We analyzed for the presence of major composite infection (MCI), major adverse cardiac events (MACE), 30-day readmission, 30-day mortality, in-hospital complications, length of stay and airway management outcomes.
Results: MCI was higher in the SSc compared to the control cohort [adjusted odds ratio (ORadj)=5.02 (95%CI: 2.47-10.20) p<0.001]. Surgical site infection (3.5% vs. 0%, p<0.001), and other infection types (5% vs. 0%, p<0.001) were higher in the SSc cohort. MACE was not significantly different between SSc vs. Control groups [6.2% vs. 7.9%, ORadj=1.33 (95%CI: 0.61-2.91) p=0.48]. Higher rates of limited cervical range of motion (13.6% vs. 3.5%, p<0.001), microstomia (11.5% vs. 1.3%, p<0.001) and preoperative difficult airway designation (8.7% vs. 0.5%, p<0.001) were observed in the SSc cohort. Bag mask ventilation grade was similar between groups (p=0.44). After adjustment, there was no between-group difference in Cormack-Lehane grade 3 and 4 view on direct laryngoscopy in SSc patients [ORadj = 1.86 (95%CI: 0.612 -5.66) p=0.18] but evidence of higher rates of video laryngoscopy [ORadj= 1.87 (95%CI:1.07 - 3.27) p=0.03]. Length of stay [median: 0.2 vs. 0.3 days, p=0.08], 30-day mortality [1.2% vs. 0.6%, ORadj=2.79 (95%CI: 0.50-15.6) p=0.24] and readmission [11.5% vs. 8.1%, ORadj=1.64 (95%CI: 0.96 – 2.82) p=0.07] were not statistically significant.
Conclusions: SSc patients demonstrate mostly similar rates of MACE, 30-day mortality, length of stay intraoperative and airway complications. There is evidence of increased risk of overall 30-day MCI risk and readmission after endoscopic procedures.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Denton CP, Khanna D. Systemic sclerosis. Lancet (London, England). 2017;390(10103):1685-1699.
3. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis and rheumatism. 2013;65(11):2737-2747.
4. Kanter GJ, Barash PG. Undiagnosed scleroderma in a patient with a difficult airway. Yale J Biol Med. 1998;71(1):31-33.
5. Shionoya Y, Kamiga H, Tsujimoto G, Nakamura E, Nakamura K, Sunada K. Anesthetic Management of a Patient With Systemic Sclerosis and Microstomia. Anesth Prog. 2020;67(1):28-34.
6. Carr ZJ, Klick J, McDowell BJ, Charchaflieh JG, Karamchandani K. An Update on Systemic Sclerosis and its Perioperative Management. Curr Anesthesiol Rep. 2020:1-10.
7. Luo Y, Jiang C, Krittanawong C, et al. Systemic sclerosis and the risk of perioperative major adverse cardiovascular events for inpatient non-cardiac surgery. Int J Rheum Dis. 2019;22(6):1023-1028.
8. Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int. 2017;37(6):853-863.
9. Marie I, Levesque H, Ducrotté P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96(1):77-83.
10. Brandler JB, Sweetser S, Khoshbin K, Babameto M, Prokop LJ, Camilleri M. Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review. Am J Gastroenterol. 2019;114(12):1847-1856.
11. Dupont R, Longué M, Galinier A, et al. Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review. Autoimmun Rev. 2018;17(11):1081-1089.
12. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
13. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
14. Kheterpal S, Martin L, Shanks AM, Tremper KK. Prediction and outcomes of impossible mask ventilation: a review of 50,000 anesthetics. Anesthesiology. 2009;110(4):891-897.
15. Birkhan J, Heifetz M, Haim S. Diffuse cutaneous scleroderma: an anaesthetic problem. Anaesthesia. 1972;27(1):89-90.
16. D'Eramo C, Zuccoli P, Monica M, Stocchetti N, Volta F, Scandellari R. [Anesthesiologic management in scleroderma patients. Presentation of a clinical case]. Acta Biomed Ateneo Parmense. 1986;57(1-2):33-37.
17. Hseu SS, Sung CS, Mao CC, Tsai SK, Lee TY. Anesthetic management in a parturient with progressive systemic sclerosis during cesarean section--a case report. Acta Anaesthesiol Sin. 1997;35(3):161-166.
18. Ye F, Kong G, Huang J. Anesthetic management of a patient with localised scleroderma. Springerplus. 2016;5(1):1507.
19. Nikai T, Kanata K, Ozasa H, Uchida H. [Suddenly developing low output syndrome during acute thoracic aortic dissection surgery in a patient with progressive systemic sclerosis]. Masui. 2002;51(2):182-185.
20. Kihira C, Mizutani H, Shimizu M. Sinus arrest developed during gastric cancer operation in a progressive systemic sclerosis patient. J Dermatol. 1995;22(5):357-359.
21. Crincoli V, Fatone L, Fanelli M, et al. Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. Int J Mol Sci. 2016;17(7).
22. Gomes da Silva GS, Maymone de Melo ML, Leao JC, et al. Oral features of systemic sclerosis: A case-control study. Oral Dis. 2019;25(8):1995-2002.
23. Zaouter C, Calderon J, Hemmerling TM. Videolaryngoscopy as a new standard of care. Br J Anaesth. 2015;114(2):181-183.
24. An JX, Zhang LM, Sullivan EA, Guo QL, Williams JP. Intraoperative cardiac arrest during anesthesia: a retrospective study of 218,274 anesthetics undergoing non-cardiac surgery. Chin Med J (Engl). 2011;124(2):227-232.
25. Forrest JB, Cahalan MK, Rehder K, et al. Multicenter study of general anesthesia. II. Results. Anesthesiology. 1990;72(2):262-268.
26. Alivernini S, De Santis M, Tolusso B, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009;60(3):426-435.
27. Galluccio F, Matucci-Cerinic M. Registry evaluation of digital ulcers in systemic sclerosis. Int J Rheumatol. 2010;2010.
28. Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology. 2010;49(7):1374-1382.
29. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815.
30. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290-2298.
31. Smilowitz NR, Armanious A, Bangalore S, Ramakrishna H, Berger JS. Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery. Am J Cardiol. 2019;123(9):1532-1537.
32. Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. Ann Thorac Surg. 2000;69(3):823-828.
33. Strange G, Stewart S, Celermajer DS, et al. Threshold of Pulmonary Hypertension Associated With Increased Mortality. J Am Coll Cardiol. 2019;73(21):2660-2672.
34. Lefevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412-2423.
35. Hu Y, Chi L, Kuebler WM, Goldenberg NM. Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells. 2020;9(11).
36. Florentin J, Dutta P. Origin and production of inflammatory perivascular macrophages in pulmonary hypertension. Cytokine. 2017;100:11-15.